A meta-analysis of andexanet alfa and prothrombin complex concentrate in the treatment of factor Xa inhibitor-related major bleeding.

ABSTRACT:

Background

Andexanet alfa (andexanet) and prothrombin complex concentrate (PCC) are both reversal agents for major bleeding in patients using factor Xa inhibitors (FXaIs). Our aim was to evaluate the current evidence for the effectiveness and safety of andexanet and PCC in a systematic review and meta-analysis.

Objectives

Primary objective was hemostatic effectiveness. Secondary objectives were thromboembolic event rate and mortality.

Methods

A systematic review was performed in PubMed and Embase. Studies describing the effectiveness and/or safety of PCC or andexanet in patients with major bleeding using FXaIs were included. Meta-analysis was performed using a random-effects model.

Results

Seventeen PCC studies, 3 andexanet studies, and 1 study describing PCC a

SUBMITTER: Jaspers T 

PROVIDER: S-EPMC8143276 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature